The most robust single agent activity reported to date in high-risk neuroblastoma preclinical models is the ALK inhibitor lorlatinib specific to ALK mutated models73, where a clear mechanistic basis was tested and translated to robust clinical activity74. The gene discussed is ALK; the disease is neuroblastoma.